[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@Gantosj Avatar @Gantosj Joe

Joe posts on X about $srpt, sarepta therapeutics, $atbpf, $ateto the most. They currently have XXXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.

Engagements: XXXXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXXXXX #

Followers Line Chart

CreatorRank: XXXXXXXXX #

CreatorRank Line Chart

Social Influence #

Social category influence stocks XXXXX% finance XXXXX% cryptocurrencies XXXX% countries XXXX%

Social topic influence $srpt #175, sarepta therapeutics 12.24%, $atbpf 8.16%, $ateto 6.12%, $lib #1, $vltlf #1, $vrtx 6.12%, $cnvifs 4.08%, $cnviv 4.08%, $cnvif XXXX%

Top accounts mentioned or mentioned by @burchetjohn @sellcalls @chimeraresearch @soreformore @biopharmiq @seedy19tron @dpfinancials @livingothedge

Top assets mentioned Sarepta Therapeutics, Inc. (SRPT) Vertex Protocol (VRTX) AST SpaceMobile, Inc. Class A Common Stock (ASTS)

Top Social Posts #

Top posts by engagements in the last XX hours

"$CNVIF $CNVI.v Capital structure Way undervalued when we look at many M&A deals in cardiovacular space & many large medical devices would try to get the hybrid device & add it to their imaging portfolio that gives CNVI a multibagger potential in a very short time"
@Gantosj Avatar @Gantosj on X 2025-06-12 18:19:34 UTC 13.3K followers, 4554 engagements

"$SRPT Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants X Years Old at Time of Treatment"
@Gantosj Avatar @Gantosj on X 2025-05-16 13:02:45 UTC 13.3K followers, 7810 engagements

"$SRPT Strategic restructuring includes reduced operating expenses delivering approximately $XXX million in anticipated annual cost savings and implementing a XX% workforce reduction of approximately XXX employees"
@Gantosj Avatar @Gantosj on X 2025-07-16 20:05:11 UTC 13.3K followers, 11.3K engagements

"This non-opioid #pain drug in very interesting with potential to become Best-in-Class #NSAID with no to very low risk of GI AEs & bleeding #ulcer $ATBPF $ATE.to will start Ph-2 trial in Q1-2024 so any time during March is expected"
@Gantosj Avatar @Gantosj on X 2024-02-20 17:01:31 UTC 13.3K followers, 2507 engagements

"When it comes to innovation & new technology investing in $VLTLF $LIB these days reminds me of the tough days $ASTS investors went through when short-sellers were steering the price & exploiting every delay or financing uncertainty. Back in April 2024 $ASTS plummeted to a 52-week low of $XXXX & fast forward to today ASTS become a favorite among loyal investors who held firm & kept averaging down. Now $ASTS trading at $XX with even more upside potential ahead its a reminder of the power of conviction and patience @spacanpanman @ASTS_SpaceMob @ASTS_Investors @fierro7676 @StunningFeline"
@Gantosj Avatar @Gantosj on X 2025-07-17 19:37:32 UTC 13.3K followers, 4777 engagements

"$SRPT Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term Sustainable Growth and Provides Update on ELEVIDYS Label"
@Gantosj Avatar @Gantosj on X 2025-07-16 20:03:12 UTC 13.3K followers, 4073 engagements

"$SRPT Duchenne portfolio continues to deliver stable and robust revenues with preliminary quarterly results showing total net product revenue of $XXX million for the second quarter 2025"
@Gantosj Avatar @Gantosj on X 2025-07-16 20:07:08 UTC 13.3K followers, 13.5K engagements

"Actually $ATBPF $ATE.to reiterate the Ph-2 "On track to launch upgraded Ph-2 abdominoplasty trial in March 2024" What I like about the Ph-2 in pain that it's fast to recruit & to get the data since the follow-up is for a very short period of X week. So results would be released in Q3"
@Gantosj Avatar @Gantosj on X 2024-02-21 14:26:16 UTC 13.3K followers, 2246 engagements

"Just think about this #Undervalued & Under-The-Radar investment with a multibagger potential $VLTLF $LIB The Permian Basin in #Texas generates 19million barrels per day of brine at lithium concentrations avg. 30ppm translating to a conservative 170000 tonnes per annum of potential LCE. The Williston Basin Bakken in #NorthDakota production ranges from 1.6million to 2m barrels of brine per day suggesting potential production of 50000 tpa LCE. X Tonne of #Lithium in the US worth around $15K-20K"
@Gantosj Avatar @Gantosj on X 2025-07-17 19:00:49 UTC 13.3K followers, 4892 engagements

"$CNVI.v $CNVIF's CEO: "The market risk is really low at this level. In fact it's a hot time in the market for products like ours. Our technology risk has been retired with regard to our next generation development & regulatory risk will be low because we have a 510K application with our own product at as its predicate and lastly our our finance or capital risk has been reduced because we have just raised $XX million in financing.""
@Gantosj Avatar @Gantosj on X 2025-07-03 18:22:02 UTC 13.3K followers, 2217 engagements

"$SRPT New protocol for immunosuppressive regimen with X months study"
@Gantosj Avatar @Gantosj on X 2025-07-16 20:51:57 UTC 13.3K followers, 7907 engagements

"$CRI.v $CRICF Insiders are buying new CEO Conan bought 2million shares & holding total of 7.1M shares. Also Malik the largest shareholder bough another 1M shares to get a total of 34.46M shares Insiders can sell for multiple reasons but they will buy for only ONE reason CONFIDENCE in the company & LT opportunity Another #Polymetallic discovery in #Canada"
@Gantosj Avatar @Gantosj on X 2025-07-11 15:20:48 UTC 13.3K followers, 2031 engagements

"$CRI.v $CRICF continue to surprise the street with high grade Zinc results & up another XXXXX% today to C$0.095 on huge volume 3.2M shares Sophisticated mining investors are joining Churchill Reports High-Grade Zinc Results on Polymetallic Veinsat the Black Raven Property Central Newfoundland"
@Gantosj Avatar @Gantosj on X 2025-07-08 16:58:36 UTC 13.3K followers, 2042 engagements

"Interesting $ATBPF $ATE.to is going for pivotal trial Ph-2 trial enhancements include the use of a placebo arm an increased sample size to XXX patient & the use of adaptive design methodology these enhancements may enable it to qualify as a pivotal trial for the FDA"
@Gantosj Avatar @Gantosj on X 2024-02-14 12:15:56 UTC 13.3K followers, 1524 engagements

"$SRPT Sarepta Therapeutics to Announce First Quarter 2025 Financial Results Tuesday May X 2025. and conference call at 4:30pm ET"
@Gantosj Avatar @Gantosj on X 2025-04-22 12:57:43 UTC 13.3K followers, 1934 engagements

"$SRPT is eligible to receive up to $103.5M in near-term regulatory and commercial milestone payments Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS a Gene Therapy to Treat Duchenne Muscular Dystrophy"
@Gantosj Avatar @Gantosj on X 2025-05-13 13:47:36 UTC 13.3K followers, 2758 engagements

"The key to the kingdom is going to be onset. It's where $VRTX failed with VX-548 Ask yourself would you take a drug that needs X hours to show any meaningful effect after bunion surgery Or 2hrs after tummy-tuck surgery Patients will call the nurse every 10min $ATBPF 60min - Safe next-generation #NSAID with enhanced safety for stand-alone or multimodal use"
@Gantosj Avatar @Gantosj on X 2024-01-31 13:44:33 UTC 13.3K followers, 3662 engagements

"$VLTLF $LIB The results from the Field Trial confirmed the performance against the R&D Centre by achieving an average XX% lithium extraction rate from Bakkenregion oilfield brine. The field trial was conducted at Compass Energy Systems Blue Marlin salt-water-disposal facility #NorthDakota"
@Gantosj Avatar @Gantosj on X 2025-07-17 17:34:20 UTC 13.3K followers, 3071 engagements

"$SRPT Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs U.S. FDA has confirmed that screening and dosing may proceed in Study SRP-9005-101 for LGMD2C/R5"
@Gantosj Avatar @Gantosj on X 2025-04-15 12:35:32 UTC 13.3K followers, 4625 engagements